Cyclosporin A Treatment for Kawasaki Disease Refractory to Initial and Additional Intravenous Immunoglobulin
Authors:
- Hiroyuki SuzukiHSHiroyuki Suzuki
- Masaru TeraiMTMasaru Terai
- Hiromichi HamadaHHHiromichi Hamada
- Takafumi HondaTHTakafumi Honda
- Tomohiro SuenagaTSTomohiro Suenaga
- Takashi TakeuchiTTTakashi Takeuchi
- Norishige YoshikawaNYNorishige Yoshikawa
- Shoichi ShibutaSSShoichi Shibuta
- Masakazu MiyawakiMMMasakazu Miyawaki
- Ko OishiKOKo Oishi
- Hironobu YamagaHYHironobu Yamaga
- Noriyuki AoyagiNANoriyuki Aoyagi
- 1 October 2011
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 30 (10) , 871-876
Abstract
Background: There are still no definite treatments for refractory Kawasaki disease (KD). In this pilot study, we evaluated the use of cyclosporin A (CyA) treatment in patients with refractory KD. Methods: We prospectively collected clinical data of CyA treatment (4–8 mg/kg/d, oral administration) for refractory KD patients using the same protocol among several hospitals. Refractory KD is defined as the persistence or recurrence of fever (37.5°C or more of an axillary temperature) at the end of the second intravenous immunoglobulin (2 g/kg) following the initial one. Results: Subjects were enrolled out of 329 KD patients who were admitted to our 8 hospitals between January 2008 and June 2010. Among a total of 28 patients of refractory KD treated with CyA, 18 (64.3%) responded promptly to be afebrile within 3 days and had decreased C-reactive protein levels, the other 4 became afebrile within 4 to 5 days. However, 6 patients (21.4%) failed to become afebrile within 5 days after the start of CyA and/or high fever returned after becoming afebrile within 5 days. Although hyperkalemia developed in 9 patients at 3 to 7 days after the start of CyA treatment, there were no serious adverse effects such as arrhythmias. Four patients (1.2%), 2 before and the other 2 after the start of CyA treatment, developed coronary arterial lesions. Conclusion: CyA treatment is considered safe and well tolerated, and a promising option for patients with refractory KD. Further investigations will be needed to clarify optimal dose, safety, and timing of CyA treatment.Keywords
This publication has 27 references indexed in Scilit:
- Marker of T‐cell activation is elevated in refractory Kawasaki diseasePediatrics International, 2010
- Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndromePediatric Nephrology, 2009
- Infliximab Treatment of Intravenous Immunoglobulin–Resistant Kawasaki DiseaseThe Journal of Pediatrics, 2008
- Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki diseaseEuropean Journal of Pediatrics, 2008
- Low-dose Methotrexate Therapy for Intravenous Immunoglobulin-resistant Kawasaki DiseaseYonsei Medical Journal, 2008
- ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysmsNature Genetics, 2007
- T cell activation profiles in Kawasaki syndromeClinical and Experimental Immunology, 2007
- A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: Clinical course and coronary artery outcomeThe Journal of Pediatrics, 2006
- Infliximab treatment for refractory Kawasaki syndromeThe Journal of Pediatrics, 2005
- The Role of T Cells in Kawasaki DiseaseCritical Reviews in Immunology, 1995